[
  {
    "ts": null,
    "headline": "5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential",
    "summary": "These five laggards of this year have double-digit upside left for the rest of 2024. These are: ADBE, PFE, DG, SNAP, RYAAY.",
    "url": "https://finnhub.io/api/news?id=10de24375a1e5d3708a77ee2d1c2bb3028f5fae25b8ef11b03923601e0396727",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732129200,
      "headline": "5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential",
      "id": 131521334,
      "image": "https://media.zenfs.com/en/zacks.com/124f1f4e4fcc578e5486ea52e0d08740",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These five laggards of this year have double-digit upside left for the rest of 2024. These are: ADBE, PFE, DG, SNAP, RYAAY.",
      "url": "https://finnhub.io/api/news?id=10de24375a1e5d3708a77ee2d1c2bb3028f5fae25b8ef11b03923601e0396727"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Climbs as Obesity-Drug Makers Rebound - Health Care Roundup",
    "summary": "Health-care companies rose as obesity-drug makers snapped back from a recent selloff. Pfizer elevated the executive in charge of its cancer-drugs business to oversee all of the drugmaker's...",
    "url": "https://finnhub.io/api/news?id=4368620816654469338d86d2cc4ac511c349474c13c7d9f63d491889b3a587a2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732123634,
      "headline": "Health Care Climbs as Obesity-Drug Makers Rebound - Health Care Roundup",
      "id": 131520068,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Health-care companies rose as obesity-drug makers snapped back from a recent selloff. Pfizer elevated the executive in charge of its cancer-drugs business to oversee all of the drugmaker's...",
      "url": "https://finnhub.io/api/news?id=4368620816654469338d86d2cc4ac511c349474c13c7d9f63d491889b3a587a2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ac0a8421b5931564bf9c1275702e9fe627800396a669767893ec1d67350f1064",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732120740,
      "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "id": 131531061,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ac0a8421b5931564bf9c1275702e9fe627800396a669767893ec1d67350f1064"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief",
    "summary": "Pfizer Names Chris Boshoff as R&D Chief Amid Strategic Focus on Innovation",
    "url": "https://finnhub.io/api/news?id=853f297067bd8b9a49b593ebb2f0073a8e52c909ac46069fe63b9ce08d94db0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732118883,
      "headline": "Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief",
      "id": 131535123,
      "image": "https://s.yimg.com/ny/api/res/1.2/LtDRrn.pCFlCkdaClzYgEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01Mjk-/https://media.zenfs.com/en/us.finance.gurufocus/896904febd776c0eb87d0b1509bf1053",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Names Chris Boshoff as R&D Chief Amid Strategic Focus on Innovation",
      "url": "https://finnhub.io/api/news?id=853f297067bd8b9a49b593ebb2f0073a8e52c909ac46069fe63b9ce08d94db0b"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan",
    "summary": "BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.",
    "url": "https://finnhub.io/api/news?id=071d60955b3ebf330cb3ebba0a2a98714d531f1774a4304bd56d92e4694b07e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732113000,
      "headline": "Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan",
      "id": 131523381,
      "image": "https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.",
      "url": "https://finnhub.io/api/news?id=071d60955b3ebf330cb3ebba0a2a98714d531f1774a4304bd56d92e4694b07e2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Announces New Chief Scientific Officer and President, Research & Development",
    "summary": "NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff wi",
    "url": "https://finnhub.io/api/news?id=457a5838cbdd8eedf8084d1ad1c82b2ee13902ace27619d3391c70bea14a30c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732103100,
      "headline": "Pfizer Announces New Chief Scientific Officer and President, Research & Development",
      "id": 131501499,
      "image": "https://media.zenfs.com/en/business-wire.com/3ca413d6181553dfd26565205edeecea",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff wi",
      "url": "https://finnhub.io/api/news?id=457a5838cbdd8eedf8084d1ad1c82b2ee13902ace27619d3391c70bea14a30c1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer names oncology head Chris Boshoff as R&D chief",
    "summary": "The appointment comes at a time when Pfizer is facing criticism from activist investor Starboard for overspending on big acquisitions and failing to produce profitable new drugs from those deals or its internal research and development.  The New York-based drugmaker, under CEO Albert Bourla, poured money into new deals to bolster its business, which has been struggling with a sharp fall in sales of its COVID vaccine and antiviral Paxlovid from the pandemic highs.  Pfizer, which is now looking to strengthen its focus on cancer drugs, said Boshoff will take on the role of chief scientific officer starting Jan. 1 and oversee all functions of research & development across all therapeutic areas.",
    "url": "https://finnhub.io/api/news?id=8f30e7bb93b9af78bef57ba46164867384aee56c7b31bd14942cf7476e13737d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732102046,
      "headline": "Pfizer names oncology head Chris Boshoff as R&D chief",
      "id": 131501500,
      "image": "https://media.zenfs.com/en/reuters.com/4f0ceb146e17f03afc272ef0958499d4",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The appointment comes at a time when Pfizer is facing criticism from activist investor Starboard for overspending on big acquisitions and failing to produce profitable new drugs from those deals or its internal research and development.  The New York-based drugmaker, under CEO Albert Bourla, poured money into new deals to bolster its business, which has been struggling with a sharp fall in sales of its COVID vaccine and antiviral Paxlovid from the pandemic highs.  Pfizer, which is now looking to strengthen its focus on cancer drugs, said Boshoff will take on the role of chief scientific officer starting Jan. 1 and oversee all functions of research & development across all therapeutic areas.",
      "url": "https://finnhub.io/api/news?id=8f30e7bb93b9af78bef57ba46164867384aee56c7b31bd14942cf7476e13737d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Names New R&D Chief",
    "summary": "Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.",
    "url": "https://finnhub.io/api/news?id=9c78cb3cc107b4a56e711c94b65d8e875f79df4611b1edf7514d55c812bba038",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732101300,
      "headline": "Pfizer Names New R&D Chief",
      "id": 131501502,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.",
      "url": "https://finnhub.io/api/news?id=9c78cb3cc107b4a56e711c94b65d8e875f79df4611b1edf7514d55c812bba038"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, under pressure to change, names oncology head as new R&D chief",
    "summary": "Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.",
    "url": "https://finnhub.io/api/news?id=522ee7723f89ceb36abfd3b273a921b7ca1700f93cf96827ca9c0e79c9ab4ba9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732101154,
      "headline": "Pfizer, under pressure to change, names oncology head as new R&D chief",
      "id": 131535130,
      "image": "https://imgproxy.divecdn.com/-h7UQSTQgmjdiU9d494NUkM2_dT0JD72I0G-UY2YxyU/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0OTE0ODQwMzEuanBn.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.",
      "url": "https://finnhub.io/api/news?id=522ee7723f89ceb36abfd3b273a921b7ca1700f93cf96827ca9c0e79c9ab4ba9"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time to Sell Eli Lilly and Pfizer Stocks?",
    "summary": "Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE).  When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine.  Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid.",
    "url": "https://finnhub.io/api/news?id=97d714c48be52e75f078cb155518df6c8e046987873567520b6e6ef4c201c5ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732099680,
      "headline": "Is It Time to Sell Eli Lilly and Pfizer Stocks?",
      "id": 131499488,
      "image": "https://g.foolcdn.com/editorial/images/798328/scientist-with-head-down.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE).  When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine.  Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid.",
      "url": "https://finnhub.io/api/news?id=97d714c48be52e75f078cb155518df6c8e046987873567520b6e6ef4c201c5ca"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Biotechnology Discovery Fund Q3 2024 Commentary",
    "summary": "Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=430107a11e6198edece261d730125acfb012b52d917ba59e2778e4e7a632b2ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732099500,
      "headline": "Franklin Biotechnology Discovery Fund Q3 2024 Commentary",
      "id": 131504006,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/169999232/image_169999232.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=430107a11e6198edece261d730125acfb012b52d917ba59e2778e4e7a632b2ca"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors",
    "summary": "NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inhibitors or severe hemophilia B (congenital factor IX [FIX] deficiency, FIX <1%) without FIX inhibitors.",
    "url": "https://finnhub.io/api/news?id=696e5da50fa20114d100eeb03cfd721ad231771a94f3397d32b32af70522b7a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732093200,
      "headline": "European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors",
      "id": 131497484,
      "image": "https://media.zenfs.com/en/business-wire.com/c09c5a639251908fe3a141e277f8dae5",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inhibitors or severe hemophilia B (congenital factor IX [FIX] deficiency, FIX <1%) without FIX inhibitors.",
      "url": "https://finnhub.io/api/news?id=696e5da50fa20114d100eeb03cfd721ad231771a94f3397d32b32af70522b7a8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Marketing authorization for Hympavzi in the EU",
    "summary": "Pfizer reports that the European Commission has granted marketing authorization for Hympavzi for the treatment of severe hemophilia in adults and adolescents without inhibitors in the European...",
    "url": "https://finnhub.io/api/news?id=a4bedbdab2f4978fe96eed4f8b602a843bb5d6ad56d0abbfee77e6eeecc6141d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732090995,
      "headline": "Pfizer: Marketing authorization for Hympavzi in the EU",
      "id": 131501322,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer reports that the European Commission has granted marketing authorization for Hympavzi for the treatment of severe hemophilia in adults and adolescents without inhibitors in the European...",
      "url": "https://finnhub.io/api/news?id=a4bedbdab2f4978fe96eed4f8b602a843bb5d6ad56d0abbfee77e6eeecc6141d"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys",
    "summary": "Investment activity in October focused on Business Development Companies. Check out my portfolio, my main picks, and my target for 2024.",
    "url": "https://finnhub.io/api/news?id=ee2c0c1844905ec03a4c7fe82d622e1f1a4eac7b2c437722a3c253267dbcb25d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732090200,
      "headline": "My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys",
      "id": 131501184,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Investment activity in October focused on Business Development Companies. Check out my portfolio, my main picks, and my target for 2024.",
      "url": "https://finnhub.io/api/news?id=ee2c0c1844905ec03a4c7fe82d622e1f1a4eac7b2c437722a3c253267dbcb25d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: new Chief Scientific Officer on January 1",
    "summary": "Pfizer announces the appointment of Chris Boshoff as Chief Scientific Officer and President, Research and Development, effective January 1, 2025, succeeding Mikael Dolsten, whose departure from the...",
    "url": "https://finnhub.io/api/news?id=c74ec4dc88a70e42fde9eecc7a69310e36769cf328685d13cc3fb38eb8d28798",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732088601,
      "headline": "Pfizer: new Chief Scientific Officer on January 1",
      "id": 131500420,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer announces the appointment of Chris Boshoff as Chief Scientific Officer and President, Research and Development, effective January 1, 2025, succeeding Mikael Dolsten, whose departure from the...",
      "url": "https://finnhub.io/api/news?id=c74ec4dc88a70e42fde9eecc7a69310e36769cf328685d13cc3fb38eb8d28798"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer taps oncology chief to map drug-research path amid pressure from activist Starboard",
    "summary": "Pfizer taps oncology chief to map drug-research path amid pressure from activist Starboard",
    "url": "https://finnhub.io/api/news?id=9874b02c9c123ef3ef24d916e6e17d708739bddf2cac28a57f66d008815896f1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732088040,
      "headline": "Pfizer taps oncology chief to map drug-research path amid pressure from activist Starboard",
      "id": 131508363,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer taps oncology chief to map drug-research path amid pressure from activist Starboard",
      "url": "https://finnhub.io/api/news?id=9874b02c9c123ef3ef24d916e6e17d708739bddf2cac28a57f66d008815896f1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Gets European Approval of Hympavzi Hemophilia Drug",
    "summary": "By Colin Kellaher Pfizer has won European Commission approval of its Hympavzi treatment for certain patients with the blood-clotting disorder hemophilia. The New York drugmaker on Wednesday...",
    "url": "https://finnhub.io/api/news?id=1e568f59458cdf5ab69e7e76b41c55b3237683618f1c12b43b5ce52efc417169",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732086328,
      "headline": "Pfizer Gets European Approval of Hympavzi Hemophilia Drug",
      "id": 131499665,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Pfizer has won European Commission approval of its Hympavzi treatment for certain patients with the blood-clotting disorder hemophilia. The New York drugmaker on Wednesday...",
      "url": "https://finnhub.io/api/news?id=1e568f59458cdf5ab69e7e76b41c55b3237683618f1c12b43b5ce52efc417169"
    }
  },
  {
    "ts": null,
    "headline": "Flagship, Pfizer alliance yields two more startup deals",
    "summary": "Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for obesity and lung cancer, respectively, adding to collaborations it previously formed with other Flagship startups.",
    "url": "https://finnhub.io/api/news?id=7c9fb9b574b731d6e77b02ac4243cfed6b346b72034b1182e0c633d2053d0f5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732084200,
      "headline": "Flagship, Pfizer alliance yields two more startup deals",
      "id": 131501507,
      "image": "https://imgproxy.divecdn.com/E-rYPuSZ5avjYRYj6Ptxfx5jrNm6u0qrf5iXbUapb9A/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9mbGFnc2hpcF8xMV8zXzIyMzM4Ml8xLmpwZw==.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for obesity and lung cancer, respectively, adding to collaborations it previously formed with other Flagship startups.",
      "url": "https://finnhub.io/api/news?id=7c9fb9b574b731d6e77b02ac4243cfed6b346b72034b1182e0c633d2053d0f5d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer names Chris Boshoff as new R&D chief, WSJ reports",
    "summary": "Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday. ...",
    "url": "https://finnhub.io/api/news?id=9c335d83ec8307d231a5fcff00051c4f2736062b54ec187e28437680df745e05",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732084046,
      "headline": "Pfizer names Chris Boshoff as new R&D chief, WSJ reports",
      "id": 131498895,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday. ...",
      "url": "https://finnhub.io/api/news?id=9c335d83ec8307d231a5fcff00051c4f2736062b54ec187e28437680df745e05"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : Jefferies London Healthcare Conference Event Announcement",
    "summary": "For Immediate Release Media Contact: PfizerMediaRelations@Pfizer.com ...",
    "url": "https://finnhub.io/api/news?id=6c0cdbfa561279b0b8407d9b43dc15b201d5710f4c0dae34de3834252d76b646",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732079771,
      "headline": "Pfizer : Jefferies London Healthcare Conference Event Announcement",
      "id": 131498091,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "For Immediate Release Media Contact: PfizerMediaRelations@Pfizer.com ...",
      "url": "https://finnhub.io/api/news?id=6c0cdbfa561279b0b8407d9b43dc15b201d5710f4c0dae34de3834252d76b646"
    }
  }
]